XML 84 R21.htm IDEA: XBRL DOCUMENT

The Company and Summary of Significant Accounting Policies (Details) (USD $)	1 Months Ended	3 Months Ended		6 Months Ended		138 Months Ended
	Mar. 04, 2013	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013 Patients	Jun. 30, 2012	Jun. 30, 2013
Company Development Stage and Basis of Presentation (Textual) [Abstract]
Loss from operations		$ 1,198,000	$ 1,145,000	$ 2,268,000	$ 2,551,000	$ 101,411,000
Cash flows from operations				(1,740,000)	(2,633,000)	(99,161,000)
Anticipated time to start AF Trial				168 days
Number of patients company plans to enroll				200
Number of years to complete the study				2 years 6 months
Reverse stock split	1-for-6 reverse split
Revenue generated by the company						$ 0
Phase 3 heart failure (HF) trial of Gencaro
Company Development Stage and Basis of Presentation (Textual) [Abstract]
Number of patients company plans to enroll				420
Number of patients				2,708

The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.

+ References+ Details